The FDA approved Vanda Pharmaceuticals’ drug Bysanti for schizophrenia and for the acute treatment of manic or mixed episodes related to bipolar I disorder.
Bysanti is an active metabolite of Vanda’s currently approved atypical antipsychotic ...
↧